Zimbabwe has turned down a significant American healthcare agreement worth 367 million US dollars (£272m) over five years because of Washington's insistence on confidential information.
This move came to light following a government memo dated December was disclosed, indicating that President Emmerson Mnangagwa felt the agreement was "lopsided".
A government spokesperson later stated that the United States was demanding access to genetic material for scientific study and commercial gain but was unwilling to share the benefits from any future treatments.
"We are forced to start the challenging and unfortunate process of scaling back our support in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy said the US had donated over $1.9bn for health programmes to Zimbabwe over the last two decades.
A physicians' group in Zimbabwe has appealed for further dialogue to find a deal acceptable to both sides so the country's vital HIV treatment initiative can continue.
Wider Context
Zimbabwe's decision follows a comparable situation in Kenya, where a court halted a related deal with the US following concerns were raised about the security of citizens' medical information.
Since resuming office recently, US President Donald Trump has slashed overseas assistance and closed the key foreign aid agency.
USAID had managed aid for the US government, but Trump claimed its spending was "inefficient" and his government was seeking direct bilateral deals to boost transparency and responsibility.
According to reports, 16 African countries have so far agreed to similar agreements, representing over $18.3bn of fresh investment.
Specifics of the Declined Deal
The money for Zimbabwe would have gone towards "HIV/Aids treatment and prevention, TB, malaria, maternal and child health, and disease outbreak preparedness.
"It is our view this cooperation might have yielded significant benefits for Zimbabwean communities, especially the 1.2 million presently receiving HIV treatment via US-supported programmes," the Ambassador added.
However, official spokesman Nick Mangwana said the proposed deal was "asymmetrical".
"Zimbabwe was being asked to provide its genetic material and health information for a long time, with no equivalent assurance of access to any medical innovations – like new medicines or tests – that could be developed from that provided information," Mangwana explained.
"Put simply, our nation would provide the basic resources for scientific discovery without any assurance that the end products would be accessible to our people if a new health crisis emerge."
National Interest and Global Health
He also noted that the US's withdrawal from the World Health Organization (WHO) and its push of one-on-one deals were undermining structures already established via the global health agency.
Mangwana cited its Pathogen Access and Benefit Sharing system created to manage potential pandemics.
"This framework is designed to guarantee that when a country provides its samples, the resulting advantages – including medicines and cures – are shared equitably, not monopolised exclusively by those with the resources to create them."
These objections regarding the US deal "must not be interpreted as opposition to America," he added.
"We are open to ongoing dialogue with our US partners on how subsequent co-operation might be arranged in a way that honours the sovereignty and interests of each country."
Medical Community Response
The Zimbabwe College of Public Health Physicians (ZCPHP) expressed it recognised the official position, but suggested that negotiations must proceed considering a large portion of the nation's Aids initiatives relied on international support.
"Where technical issues arise, such as those relating to information security or agreement terms, these can frequently be resolved via detailed discussion and negotiated safeguards," the group said.
The halted deal highlights the continuing debate between accepting crucial foreign assistance and protecting local interests in an ever more data-driven world.